LEXINGTON, Mass.--(BUSINESS WIRE)--Orphan Technologies, a company dedicated to helping patients control their homocysteine levels, today announced that the first patients have been treated in a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback